Switch theme
Sign up to access all valuation multiples
Gubra AS is a specialized preclinical CRO and biotech company focused on peptide-based drug discovery within metabolic and fibrotic diseases. The company has three segments: Pre-clinical contract research (CRO), which derives maximum revenue; Discovery & Partnerships (D&P) Segment; and Gubra Green Segment. It derives maximum revenue from Pre-clinical contract research (CRO) segment. Geographically, the company operates in Europe, North America and Other regions.
2008
260
LTM Revenue $196M
LTM EBITDA $145M
$908M
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
Gubra has a last 12-month revenue (LTM) of $196M and a last 12-month EBITDA of $145M.
In the most recent fiscal year, Gubra achieved revenue of $40.0M and an EBITDA of -$3.0M.
Gubra expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Gubra valuation multiples based on analyst estimates| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue | $196M | XXX | $40.0M | XXX | XXX | XXX |
| Gross Profit | $180M | XXX | $24.8M | XXX | XXX | XXX |
| Gross Margin | 92% | XXX | 62% | XXX | XXX | XXX |
| EBITDA | $145M | XXX | -$3.0M | XXX | XXX | XXX |
| EBITDA Margin | 74% | XXX | -8% | XXX | XXX | XXX |
| EBIT | $106M | XXX | -$7.5M | XXX | XXX | XXX |
| EBIT Margin | 54% | XXX | -19% | XXX | XXX | XXX |
| Net Profit | $115M | XXX | -$5.5M | XXX | XXX | XXX |
| Net Margin | 58% | XXX | -14% | XXX | XXX | XXX |
| Net Debt | XXX | XXX | n/a | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of May 30, 2025, Gubra's stock price is DKK 390 (or $59).
Gubra has current market cap of DKK 6.4B (or $957M), and EV of DKK 6.0B (or $908M).
See Gubra trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $908M | $957M | XXX | XXX | XXX | XXX | $7.28 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Start Free TrialAs of May 30, 2025, Gubra has market cap of $957M and EV of $908M.
Gubra's trades at 22.7x EV/Revenue multiple, and -300.4x EV/EBITDA.
Equity research analysts estimate Gubra's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Gubra has a P/E ratio of 8.3x.
See valuation multiples for Gubra and 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $957M | XXX | $957M | XXX | XXX | XXX |
| EV (current) | $908M | XXX | $908M | XXX | XXX | XXX |
| EV/Revenue | 4.6x | XXX | 22.7x | XXX | XXX | XXX |
| EV/EBITDA | 6.3x | XXX | -300.4x | XXX | XXX | XXX |
| EV/EBIT | 8.5x | XXX | -120.5x | XXX | XXX | XXX |
| EV/Gross Profit | 5.0x | XXX | n/a | XXX | XXX | XXX |
| P/E | 8.3x | XXX | -174.1x | XXX | XXX | XXX |
| EV/FCF | 7.8x | XXX | -222.4x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Start Free TrialGubra's last 12 month revenue growth is 43%
Gubra's revenue per employee in the last FY averaged $0.2M, while opex per employee averaged $0.1M for the same period.
Gubra's rule of 40 is 29% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Gubra's rule of X is 181% (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
See operational valuation multiples for Gubra and other 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue Growth | 43% | XXX | 46% | XXX | XXX | XXX |
| EBITDA Margin | 74% | XXX | -8% | XXX | XXX | XXX |
| EBITDA Growth | 52% | XXX | n/a | XXX | XXX | XXX |
| Rule of 40 | 29% | XXX | 35% | XXX | XXX | XXX |
| Bessemer Rule of X | XXX | XXX | 181% | XXX | XXX | XXX |
| Revenue per Employee | XXX | XXX | $0.2M | XXX | XXX | XXX |
| Opex per Employee | XXX | XXX | $0.1M | XXX | XXX | XXX |
| S&M Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| G&A Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| R&D Expenses to Revenue | XXX | XXX | 43% | XXX | XXX | XXX |
| Opex to Revenue | XXX | XXX | 81% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Jubilant Pharmova | XXX | XXX | XXX | XXX | XXX | XXX |
| Biocon | XXX | XXX | XXX | XXX | XXX | XXX |
| Syngene International | XXX | XXX | XXX | XXX | XXX | XXX |
| Dishman Carbogen Amics | XXX | XXX | XXX | XXX | XXX | XXX |
| Cohance Lifesciences | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Gubra acquired XXX companies to date.
Last acquisition by Gubra was XXXXXXXX, XXXXX XXXXX XXXXXX . Gubra acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Start Free Trial| When was Gubra founded? | Gubra was founded in 2008. |
| Where is Gubra headquartered? | Gubra is headquartered in Denmark. |
| How many employees does Gubra have? | As of today, Gubra has 260 employees. |
| Who is the CEO of Gubra? | Gubra's CEO is Mr. Henrik Blou. |
| Is Gubra publicy listed? | Yes, Gubra is a public company listed on CSE. |
| What is the stock symbol of Gubra? | Gubra trades under GUBRA ticker. |
| When did Gubra go public? | Gubra went public in 2023. |
| Who are competitors of Gubra? | Similar companies to Gubra include e.g. Jubilant Pharmova, Biocon, Syngene International, Dishman Carbogen Amics. |
| What is the current market cap of Gubra? | Gubra's current market cap is $957M |
| What is the current revenue of Gubra? | Gubra's last 12 months revenue is $196M. |
| What is the current revenue growth of Gubra? | Gubra revenue growth (NTM/LTM) is 43%. |
| What is the current EV/Revenue multiple of Gubra? | Current revenue multiple of Gubra is 4.6x. |
| Is Gubra profitable? | Yes, Gubra is EBITDA-positive (as of the last 12 months). |
| What is the current EBITDA of Gubra? | Gubra's last 12 months EBITDA is $145M. |
| What is Gubra's EBITDA margin? | Gubra's last 12 months EBITDA margin is 74%. |
| What is the current EV/EBITDA multiple of Gubra? | Current EBITDA multiple of Gubra is 6.3x. |
| What is the current FCF of Gubra? | Gubra's last 12 months FCF is $116M. |
| What is Gubra's FCF margin? | Gubra's last 12 months FCF margin is 59%. |
| What is the current EV/FCF multiple of Gubra? | Current FCF multiple of Gubra is 7.8x. |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
